Glomerulonephritis: Clinical Trials

25 trials for Glomerulonephritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 unknown. 25 Phase 2, 7 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 225Unknown 25
Phase 37Unknown 7
Phase 14Unknown 4

Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
Dapagliflozin 10mg Tab orally once daily - Lupus Nephritis
Phase 1 / Phase 2UnknownAin Shams University502023-12-012023-11-02
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Placebo of SC0062, SC0062 low dose, SC0062 medium dose - Diabetic Kidney Disease, IgA Nephropathy
Phase 2UnknownBiocity Biopharmaceutics Co., Ltd.2552023-05-232025-01-07
A Study of Telitacicept in Lupus Nephritis
Telitacicept 240 mg, Telitacicept 160 mg, Placebo - Lupus Nephritis
Phase 2UnknownRemeGen Co., Ltd.1202023-04-172024-09-23
Study of Telitacicept in Patients With Refractory IgA Nephropathy
Telitacicept - IgA Nephropathy
Phase 2 / Phase 3UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine402023-03-012023-02-24
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
Sirolimus - Lupus Nephritis, Immunosuppression
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital202021-06-302021-05-19
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
SHR-1314, Placebo - Lupus Nephritis
Phase 2UnknownSuzhou Suncadia Biopharmaceuticals Co., Ltd.602021-06-282021-06-11
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis
Phase 1 / Phase 2UnknownAll Natural Medicine Clinic, LLC20002021-03-012021-05-26
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) - Systemic Lupus Erythematosus
Phase 2UnknownHanyang University Seoul Hospital102019-09-262021-04-08
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, Optimized Supportive Care - IgA Nephropathy at High Risk of Developing ESRD
Phase 2 / Phase 3UnknownGuang'anmen Hospital of China Academy of Chinese Medical Sciences602019-07-042024-09-25
Mesenchymal Stromal Cells (MSC“s) in Renal Lupus
MSC treatment, Standard of Care, Placebo - Lupus Erythematosus, Systemic, Lupus Glomerulonephritis
Phase 2UnknownUniversidad de los Andes, Chile392019-04-022023-02-08
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
Mesenchymal stem cells, Mycophenolate Mofetil, Placebo of Mesenchymal stem cells - Lupus Nephritis
Phase 2UnknownLingyun Sun2302018-08-012018-07-10
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
Fecal microbiota transplantation - IgA Nephropathy
Phase 2UnknownAir Force Military Medical University, China302017-11-222018-08-21
The Iguratimod Effect on Lupus Nephritis (IGeLU)
Iguratimod, Cyclophosphamide, Azathioprine - Lupus Nephritis
Phase 2UnknownRenJi Hospital1202017-09-072018-12-19
Valproic Acid for Idiopathic Nephrotic Syndrome
Valproic Acid - Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Phase 2 / Phase 3UnknownUniversitair Ziekenhuis Brussel152016-10-012017-06-20
Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
Prednisolone, Reh-acteoside - IGA Nephropathy
Phase 2 / Phase 3UnknownSun Yat-sen University752016-05-012016-02-02
ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
ACTHAR Gel (adrenocorticotropic hormone) - Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Phase 2 / Phase 3UnknownAlbany Medical College102015-02-012015-01-26
A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy
steroid & Cyclosporin - Idiopathic Membranous Nephropathy, Proteinuria
Phase 2UnknownSun Yat-sen University1802014-06-012014-07-01
A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
Methylprednisolone(intravenously in the 1st-2nd-3rd month ), Methylprednisolone(intravenously in the 1st-3rd-5th month) - Glomerulonephritis, IGA, Peripapillary Crescent
Phase 2UnknownSun Yat-sen University1802014-06-012015-03-03
The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
calcitriol, placebo - Systemic Lupus Erythematosus
Phase 2UnknownGuilan University of Medical Sciences502013-04-012013-05-29
Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis
Tripterygium wilfordii Hook F, Cyclophosphamide, GC - Nephritis, Lupus
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1302012-07-012012-07-23

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Lupus Nephritis (15)  ·  Glomerulonephritis, IGA (6)  ·  Lupus Erythematosus, Systemic (4)  ·  Nephritis (2)  ·  Proteinuria (2)  ·  Ageusia (1)  ·  Anosmia (1)  ·  Anxiety Disorders (1)  ·  Arthritis, Reactive (1)  ·  Bipolar Disorder (1)  ·  COVID-19 stress syndrome (1)  ·  Depression (1)  ·  Diabetic Nephropathies (1)  ·  Gastroesophageal Reflux (1)

Broader conditions

Female Urogenital Diseases (25)  ·  Female Urogenital Diseases and Pregnancy Complications (25)  ·  Kidney Diseases (25)  ·  Male Urogenital Diseases (25)  ·  Urogenital Diseases (25)  ·  Urologic Diseases (25)  ·  Immune System Diseases (24)  ·  Autoimmune Diseases (23)  ·  Nephritis (23)  ·  Connective Tissue Diseases (15)  ·  Skin and Connective Tissue Diseases (15)  ·  Lupus Erythematosus, Systemic (11)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Pathologic Processes (4)

Interventions

Cyclophosphamide (4)  ·  Prednisolone (2)  ·  Steroids (2)  ·  telitacicept (2)  ·  Adrenocorticotropic Hormone (1)  ·  Azathioprine (1)  ·  Calcitriol (1)  ·  Clinical Coding (1)  ·  Cyclosporine (1)  ·  Fecal Microbiota Transplantation (1)  ·  Immunosuppressive Agents (1)  ·  Mycophenolic Acid (1)  ·  RC-18 (1)  ·  Sirolimus (1)  ·  Standard of Care (1)

Sponsors

Sun Yat-sen University (3)  ·  Peking Union Medical College Hospital (2)  ·  Ain Shams University (1)  ·  Air Force Military Medical University, China (1)  ·  Albany Medical College (1)  ·  All Natural Medicine Clinic, LLC (1)  ·  Biocity Biopharmaceutics Co., Ltd. (1)  ·  CytoMed & Beike (1)  ·  Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1)  ·  Guilan University of Medical Sciences (1)  ·  Hanyang University Seoul Hospital (1)  ·  Kinki University (1)  ·  Lingyun Sun (1)  ·  Nanjing Medical University (1)  ·  Organ Transplant Institute, China (1)

Countries

China (14)  ·  South Korea (2)  ·  United States (2)  ·  Belgium (1)  ·  Chile (1)  ·  Egypt (1)  ·  Iran (1)  ·  Japan (1)

Top investigators

Zongpei Jiang, M.D. & Ph.D. (2)  ·  Alireza Amir Maafi, MD Student (1)  ·  Chan-Bum Choi, M.D.,Ph.D. (1)  ·  Cherry Kamel, Professor (1)  ·  Chunde Bao, MD (1)  ·  Fengchun Zhang, MD (1)  ·  Fernando F E, MD (1)  ·  Howaida Al-Shennawi, Professor (1)  ·  Jianghua Chen, Prof (1)  ·  Jie Wang (1)  ·  Lingyun Sun, M.D. (1)  ·  Marc A Judson, MD (1)  ·  Peter Janssens, MD (1)  ·  Shiren Sun, M.D. (1)

Results publications

PMID 38299639, PMID 28478399, PMID 30428931, PMID 31907076, PMID 34380536, PMID 34778952, PMID 35062886, PMID 38334499, PMID 39462310, PMID 40465397, PMID 42001190